Publicacións en colaboración con investigadores/as de Hospital de Poniente (16)

2024

  1. A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 8, pp. 1794-1800

  2. Early Antibiotic De-escalation in Patients With Severe Infections Due to Bloodstream Infection by Enterobacterales: A Post Hoc Analysis of a Prospective Multicentre Cohort

    International Journal of Antimicrobial Agents, Vol. 64, Núm. 5

2023

  1. Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort

    Antibiotics, Vol. 12, Núm. 1

2019

  1. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

    Pharmacogenomics Journal, Vol. 17, Núm. 4, pp. 360-365

2016

  1. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 35, Núm. 5, pp. 815-819

2015

  1. Evaluation of eosinophilia in immigrants in Southern Spain using tailored screening and treatment protocols: A prospective study

    Travel Medicine and Infectious Disease, Vol. 13, Núm. 4, pp. 315-321

2013

  1. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  2. Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

    PLoS ONE, Vol. 8, Núm. 7

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205

  2. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

    AIDS, Vol. 26, Núm. 8, pp. 1009-1015

2011

  1. Present-day treatment of tuberculosis and latent tuberculosis infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. SUPPL. 1, pp. 41-46

  2. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 6, pp. 1351-1353

2010

  1. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 10, pp. 2204-2211

  2. Does lopinavir/ritonavir alter the primary gingival epithelium?

    Expert Review of Anti-Infective Therapy, Vol. 8, Núm. 12, pp. 1345-1349

2009

  1. Factores de riesgo cardiovascular dependientes del tratamiento antirretroviral

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 27, Núm. SUPPL. 1, pp. 24-32